Viatris (VTRS) EBIT Growth (3y) (2022 - 2026)
Viatris (VTRS) EBIT Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | -59.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -74.25% |
| Mar 31, 2026 | -30.05% |
| Dec 31, 2025 | 1.44% |
| Sep 30, 2025 | -31.66% |
| Jun 30, 2025 | -24.84% |
| Mar 31, 2025 | -82.46% |
| Dec 31, 2024 | -32.33% |
| Sep 30, 2024 | -14.20% |
| Jun 30, 2024 | -71.21% |
| Mar 31, 2024 | 40.37% |
| Dec 31, 2023 | 19.80% |
| Sep 30, 2023 | 50.28% |
| Jun 30, 2023 | 76.51% |
| Mar 31, 2023 | 29.36% |
| Dec 31, 2022 | -31.99% |